GlycoMimetics Inc expected to post a loss of 16 cents a share - Earnings Preview

Crescent Biopharma

07/05/2024 19:28

* GlycoMimetics Inc  GLYC.OQ   GLYC.O  is expected to show
no
change in quarterly revenue when it reports  results on May 9
for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for GlycoMimetics Inc is for
a
loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for
GlycoMimetics Inc
is $0.75​, above​ its last closing price of $0.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.15       -0.15      -0.14     Beat    8.2
 Sep. 30 2023  -0.14       -0.14      -0.14     Met     2.3
 Jun. 30 2023  -0.18       -0.18      -0.13     Beat    29.1​
 Jan. 1 0001   -0.16       -0.17      -0.17     Met     -2
 ​​Dec.        -0.17       -0.17      -0.19     Missed  -14
 31 2022                                                
 Sep. 30 2022  -0.23       -0.26      -0.16     Beat    39.2​
 Jun. 30 2022  -0.29       -0.28      -0.25     Beat    12.3
 Mar. 31 2022  -0.31       -0.31      -0.28     Beat    8.7
 This summary was machine generated May 7 at 18:28 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)